Pfizer Continues Transformation; Stakes Future on New Direction

By Matthew Mahady
Published: Monday, May 24, 2010
Mr. Mackay said that Pfizer is making “significant operational improvements” as it works to refocus its investments, accelerate development of new therapies, and improve the execution of clinical trials. “We are investing in the most promising disease areas, where there is strong unmet medical need, favorable markets, and an opportunity to advance medical science.”

Pfizer recently announced updated safety and efficacy results from a phase II trial involving its investigational compound CP- 751871 in patients with advanced (stage III/ IV) non–small cell lung cancer (ANSCLC). CP- 751871 is a fully human monoclonal antibody and a highly specific inhibitor of the insulinlike growth factor 1 receptor (IGF1R) pathway. The IGF1R pathway is one of the key signaling pathways in cancer cells that leads to uncontrolled growth and survival of tumor cells. The randomized noncomparative study of patients with treatment-naïve ANSCLC showed that 54% receiving a treatment combination consisting of CP-751871 plus carboplatin/paclitaxel (n = 97) experienced objective responses compared with 41% of patients who received carboplatin/ paclitaxel alone (n = 53). Pfizer currently has a global phase III clinical trial registration program for CP-751871 in ANSCLC underway. In addition, Pfizer is sponsoring clinical trials to study CP-751871 as a potential treatment for many other cancers, including prostate, breast, colon, and Ewing’s sarcoma.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x